LENZ Therapeutics Net Income
| LENZ Stock | 13.97 0.65 4.45% |
As of the 5th of February, LENZ Therapeutics secures the risk adjusted performance of (0.09), and Mean Deviation of 4.34. In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of LENZ Therapeutics, as well as the relationship between them.
LENZ Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LENZ Therapeutics' valuation are provided below:Gross Profit | Market Capitalization | Enterprise Value Revenue 16.2426 | Revenue | Earnings Share (2.06) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -44.8 M | -47 M | |
| Net Loss | -44.8 M | -47 M | |
| Net Loss | (2.69) | (2.82) | |
| Net Income Per E B T | 1.15 | 1.11 |
LENZ | Net Income | Build AI portfolio with LENZ Stock |
The evolution of Net Income for LENZ Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how LENZ Therapeutics compares to historical norms and industry peers.
Latest LENZ Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of LENZ Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in LENZ Therapeutics financial statement analysis. It represents the amount of money remaining after all of LENZ Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is LENZ Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LENZ Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (49.77 M) | 10 Years Trend |
|
Net Income |
| Timeline |
LENZ Net Income Regression Statistics
| Arithmetic Mean | (21,329,106) | |
| Coefficient Of Variation | (136.97) | |
| Mean Deviation | 26,202,255 | |
| Median | (109,000) | |
| Standard Deviation | 29,214,515 | |
| Sample Variance | 853.5T | |
| Range | 70.7M | |
| R-Value | (0.73) | |
| Mean Square Error | 423.2T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (4,232,126) | |
| Total Sum of Squares | 13655.8T |
LENZ Net Income History
Other Fundumenentals of LENZ Therapeutics
LENZ Therapeutics Net Income component correlations
LENZ Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for LENZ Therapeutics is extremely important. It helps to project a fair market value of LENZ Stock properly, considering its historical fundamentals such as Net Income. Since LENZ Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LENZ Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LENZ Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LENZ Therapeutics. Expected growth trajectory for LENZ significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LENZ Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LENZ Therapeutics requires distinguishing between market price and book value, where the latter reflects LENZ's accounting equity. The concept of intrinsic value - what LENZ Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LENZ Therapeutics' price substantially above or below its fundamental value.
Understanding that LENZ Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LENZ Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LENZ Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
LENZ Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LENZ Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LENZ Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in LENZ Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding LENZ Therapeutics or generate 0.0% return on investment in LENZ Therapeutics over 90 days. LENZ Therapeutics is related to or competes with GH Research, ARS Pharmaceuticals, Nanobiotix, Maravai Lifesciences, Rezolute, Geron, and Tyra Biosciences. LENZ Therapeutics is entity of United States More
LENZ Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LENZ Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LENZ Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 40.02 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 8.05 |
LENZ Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LENZ Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LENZ Therapeutics' standard deviation. In reality, there are many statistical measures that can use LENZ Therapeutics historical prices to predict the future LENZ Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.37) | |||
| Treynor Ratio | (3.01) |
LENZ Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (3.00) | |||
| Mean Deviation | 4.34 | |||
| Coefficient Of Variation | (722.46) | |||
| Standard Deviation | 6.41 | |||
| Variance | 41.15 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.37) | |||
| Treynor Ratio | (3.01) | |||
| Maximum Drawdown | 40.02 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 8.05 | |||
| Skewness | (1.20) | |||
| Kurtosis | 4.75 |
LENZ Therapeutics Backtested Returns
LENZ Therapeutics has Sharpe Ratio of -0.11, which conveys that the firm had a -0.11 % return per unit of volatility over the last 3 months. LENZ Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify LENZ Therapeutics' risk adjusted performance of (0.09), and Mean Deviation of 4.34 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.3, which conveys not very significant fluctuations relative to the market. As returns on the market increase, LENZ Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding LENZ Therapeutics is expected to be smaller as well. At this point, LENZ Therapeutics has a negative expected return of -0.63%. Please make sure to verify LENZ Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if LENZ Therapeutics performance from the past will be repeated in the future.
Auto-correlation | 0.17 |
Very weak predictability
LENZ Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between LENZ Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LENZ Therapeutics price movement. The serial correlation of 0.17 indicates that over 17.0% of current LENZ Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 3.17 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
LENZ Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, LENZ Therapeutics reported net income of (49.77 Million). This is 114.58% lower than that of the Biotechnology sector and 171.05% lower than that of the Health Care industry. The net income for all United States stocks is 108.72% higher than that of the company.
LENZ Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LENZ Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LENZ Therapeutics could also be used in its relative valuation, which is a method of valuing LENZ Therapeutics by comparing valuation metrics of similar companies.LENZ Therapeutics is currently under evaluation in net income category among its peers.
LENZ Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, LENZ Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to LENZ Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
LENZ Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (1.51) % | ||||
| Current Valuation | 308.81 M | ||||
| Shares Outstanding | 31.29 M | ||||
| Shares Owned By Insiders | 2.52 % | ||||
| Shares Owned By Institutions | 97.47 % | ||||
| Number Of Shares Shorted | 8.73 M | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 27.77 X | ||||
| Gross Profit | 17.5 M | ||||
| EBITDA | (49.71 M) | ||||
| Net Income | (49.77 M) | ||||
| Total Debt | 1.38 M | ||||
| Book Value Per Share | 6.78 X | ||||
| Cash Flow From Operations | (59.39 M) | ||||
| Short Ratio | 8.17 X | ||||
| Earnings Per Share | (2.06) X | ||||
| Target Price | 53.71 | ||||
| Market Capitalization | 485.93 M | ||||
| Total Asset | 215.3 M | ||||
| Retained Earnings | (145.01 M) | ||||
| Working Capital | 201.51 M | ||||
| Net Asset | 215.3 M |
About LENZ Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LENZ Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LENZ Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LENZ Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.